Literature DB >> 1370335

Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans.

M Pettoello-Mantovani1, A Casadevall, T R Kollmann, A Rubinstein, H Goldstein.   

Abstract

Patients with AIDS who become infected with Cryptococcus neoformans have a poor prognosis. We speculated that the presence of cryptococcal capsular polysaccharide may enhance HIV-1 infection. In an in-vitro study, the presence of cryptococcal polysaccharide significantly increased (p less than 0.05) production of p24 antigen after infection of H9 cells with HIV-1-infected H9 cells. We also found similar results when lymphocytes from an HIV-1-infected patient were co-cultured with mononuclear cells from an uninfected individual. Our findings suggest a new pathogenic role for the capsular polysaccharide--namely, the capacity to enhance HIV-1 infectivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370335     DOI: 10.1016/0140-6736(92)90142-p

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

1.  Cryptococcal Meningitis in HIV-Infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  Cerebrospinal fluid HIV-1 viral load during treatment of cryptococcal Meningitis.

Authors:  Annemarie E Brouwer; Praprit Teparrukkul; Adul Rajanuwong; Wirongrong Chierakul; Weera Mahavanakul; Wasun Chantratita; Nicholas J White; Thomas S Harrison
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04       Impact factor: 3.731

3.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.

Authors:  R Blackstock; J W Murphy
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  New insights on the pathogenesis of invasive Cryptococcus neoformans infection.

Authors:  Helene C Eisenman; Arturo Casadevall; Erin E McClelland
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

6.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

7.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis.

Authors:  S C Lee; A Casadevall; D W Dickson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

9.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors:  J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Variables that influence HIV-1 cerebrospinal fluid viral load in cryptococcal meningitis: a linear regression analysis.

Authors:  Diego M Cecchini; Ana M Cañizal; Haroldo Rojas; Alicia Arechavala; Ricardo Negroni; María B Bouzas; Jorge A Benetucci
Journal:  J Int AIDS Soc       Date:  2009-11-11       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.